Previous 10 | Next 10 |
WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral...
WARMINSTER, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral...
2023-10-16 18:39:22 ET Summary Arbutus Biopharma Corporation is a small biopharma company focused on developing therapeutics for chronic Hepatitis B virus infection. The company recently dropped two drug candidates in development to increase focus on advancing its primary asset wi...
2023-10-11 12:26:19 ET More on Alnylam Alnylam: FDA Rejection Of Onpattro For ATTR-CM Is A Setback, But A Manageable One Alnylam: Why The FDA Rejection Of Onpattro Is A Minor Setback Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatili...
Imdusiran data will be highlighted in late breaking presentation WARMINSTER, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target ...
2023-10-09 13:48:11 ET The FDA's decision to reject a label expansion for Alnylam’s ( NASDAQ: ALNY ) amyloidosis therapy patisiran on Monday pressured shares of Arbutus Biopharma ( NASDAQ: ABUS ), which has out-licensed the product to the RNAi therapeutics company. ...
2023-09-11 17:32:50 ET More on Arbutus Biopharma Arbutus Biopharma appoints Karen Sims as chief medical officer Seeking Alpha’s Quant Rating on Arbutus Biopharma Historical earnings data for Arbutus Biopharma Financial information for Arbutus Biopharma...
Progressing development of hepatitis B virus (HBV) compounds imdusiran (AB-729) and AB-101, an oral PD-L1 inhibitor Discontinuing all coronavirus and oral RNA destabilizer programs, including AB-343 and AB-161 Extending cash runway through Q3 2025 WARMINSTER, Pa., Sept. 11...
WARMINSTER, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management t...
2023-08-30 16:04:07 ET Summary Moderna and Pfizer/BioNTech earned more than $110 billion from their COVID vaccines, with net profit margins of more than 50%. Alnylam, Arbutus and Genevant are suing Moderna, Pfizer, and BioNTech, alleging they infringed on patents for lipid nanopar...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...